Wednesday, July 8, 2026

Patent intelligence · US

US 8378107

Heteroaryl antagonists of prostaglandin D2 receptors

granted A61KA61K31/47A61K45/06A61P
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 7
Applicant portfolio 308
Patent details — US 8378107
Jurisdiction
US
Status
granted
Grant date
Feb 19, 2013
Expiration
Feb 14, 2033
Claims
19
CPC classes
A61K, A61K31/47, A61K45/06, A61P
View on Google Patents ↗

Quick answer

US 8378107 (Heteroaryl antagonists of prostaglandin D2 receptors) is held by Panmira Pharmaceuticals, LLC. Status: granted. Granted Feb 19, 2013. Expires Feb 14, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
19
CPC classes
A61K, A61K31/47, A61K45/06, A61P, A61P11/00, A61P11/02

More from Panmira Pharmaceuticals, LLC

Related pharmaceutical patents in our USPTO index.

  1. US 12421228

    Naphthyridine derivatives as PRC2 inhibitors

    Mirati Therapeutics, Inc. · Expires Sep 18, 2045

    granted
  2. US 12421253

    Tetrahydropyridopyrimidine pan-KRas inhibitors

    Mirati Therapeutics, Inc. · Expires Sep 18, 2045

    granted
  3. US 12414911

    Topical compositions and methods of use

    MIRACLE FRUIT OIL L.L.C. · Expires Sep 11, 2045

    granted
  4. US 12412764

    Substrate-accommodating container

    MIRAIAL CO., LTD. · Expires Sep 4, 2045

    granted
  5. US 12398154

    Azaquinazoline pan-KRas inhibitors

    Mirati Therapeutics, Inc. · Expires Aug 21, 2045

    granted
  6. US 12383503

    Adagrasib solid pharmaceutical compositions

    Mirati Therapeutics, Inc. · Expires Aug 7, 2045

    granted
  7. US 12377101

    Combination therapies

    Mirati Therapeutics, Inc. · Expires Jul 31, 2045

    granted
  8. US 12371435

    Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors

    Mirati Therapeutics, Inc. · Expires Jul 24, 2045

    granted

Frequently asked questions

What is US patent 8378107?

US 8378107 (Heteroaryl antagonists of prostaglandin D2 receptors) is held by Panmira Pharmaceuticals, LLC. Status: granted. Granted Feb 19, 2013. Expires Feb 14, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 8378107?

Panmira Pharmaceuticals, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.

When does US 8378107 expire?

Our index shows an expiration date of Feb 14, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.